RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 Neoadjuvant B and N Safe and Effective with D and H in HER2-Positive Breast Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 11
OP 12
DO 10.1177/155989771436007
UL http://mdc.sagepub.com/content/14/36/11.2.abstract
AB Neoadjuvant treatment regimens resulting in high pathologic complete response (pCR) rates are needed for patients with HER2-positive breast cancer because they are correlated with favorable prognoses. Although N in combination with H is highly effective in HER2-positive breast cancer, this regimen is unsuitable because of high cardiotoxicity. The Phase 2 Study of Neoadjuvant Trastuzumab+Docetaxel+Non-pegylated Liposome-Encapsulated Doxorubicin (NPLD)±Bevacizumab in HER2-Positive Early Breast Cancer [ABCSG-32; NCT01367028] was conducted to evaluate the cardiotoxicity and efficacy of N and B in combination with DH in the neoadjuvant treatment of early HER2-positive breast cancer.